ReviewInflammopharmacology2016
Atherosclerotic cardiovascular disease: a review of initiators and protective factors.
Review in Inflammopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 5 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Effects of Single Low-Carbohydrate, High-Fat Meal Consumption on Postprandial Lipemia and Markers of Endothelial Dysfunction: A Systematic Review of Current Evidence.Nutrition reviews · 2025Pooled it
- Effects of probiotics on lipid metabolism, oxidation, and inflammation in coronary heart disease: a systematic review and meta-analysis.Frontiers in nutrition · 2025Pooled it
- Pooled it
- Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Relationship Between Polycyclic Aromatic Hydrocarbons and Cardiovascular Diseases: A Systematic Review.Frontiers in public health · 2021Pooled it
- Service delivery interventions for lipid testing and lipid-lowering therapy for primary and secondary prevention of cardiovascular disease in adults.The Cochrane database of systematic reviews · 2026Article
- Systematic review and meta-analysis of cardiovascular disease risk among hypertensive patients in Africa.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Increased potential for atherogenic changes in asthma: evidence from transcriptomic studies of arterial endothelial cells.Respiratory research · 2026Article
- Apolipoprotein A-I (CSL112) and Cardiovascular Outcomes in Atherosclerotic Cardiovascular Disease: A Scoping Review.Clinical cardiology · 2026Article
- Association between Dysgeusia and Atherosclerotic Cardiovascular Disease: A Cross-Sectional Study With Propensity Score-Matched Analyses.Oral health & preventive dentistry · 2026Article
- The higher dietary energy-to-fiber ratio is associated with an increased risk of poor blood pressure control among patients with essential hypertension: a cross-sectional study.Frontiers in nutrition · 2026Article
- Effects of moderate physical training program in post-myocardial infarction patients with arterial hypertension.European journal of translational myology · 2025Article
- Review
- Developing a Knowledge Translation Intervention to Improve the Detection and Management of Pediatric Dyslipidemias in British Columbia.CJC pediatric and congenital heart disease · 2025Article
- Dysfunction of Microcirculation in Atherosclerosis: Implications of Nitric Oxide, Oxidative Stress, and Inflammation.International journal of molecular sciences · 2025Review
- Role of annexin A7 in the occurrence and progression of coronary atherosclerosis: a narrative review.Cardiovascular diagnosis and therapy · 2025Review
- Omega-3 Fatty Acids and Exercise in Obesity Management: Independent and Synergistic Benefits in Metabolism and Knowledge Gaps.Biology · 2025Review
- Effect of Propolis Extracts on OxLDL and LOX-1 Levels in ApoE Knockout Mice Fed a High Fat Diet.Life (Basel, Switzerland) · 2025Article
- Coenzyme A metabolism: a key driver of gut microbiota dynamics and metabolic profiles.FEMS microbiology reviews · 2025Review
- Characterizing vascular function in mouse models of Alzheimer's disease, atherosclerosis, and mixed Alzheimer's and atherosclerosis.Neurophotonics · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease (CVD) is a collective term comprising of a group of disorders of the heart and blood vessels. These diseases are the largest cause of morbidity and premature death worldwide. Coronary heart disease and cerebrovascular disease (stroke) are the most frequently occurring diseases. The two major initiators involved in the development of atherosclerotic CVD are vascular production of reactive oxygen species (ROS) and lipid oxidation. In atherosclerosis development, ROS is associated with rapid loss of anti-inflammatory and anti-atherogenic activities of the endothelium-derived nitric oxide (NO(·)) resulting in endothelial dysfunction. In part involving activation of the transcription factor NF-κB, ROS have been involved in signaling cascades leading to vascular pro-inflammatory and pro-thrombotic gene expression. ROS is also a potent activator of matrix metalloproteinases (MMPs), which indicate plaque destabilization and rupture. The second initiator involved in atherosclerotic CVD is the oxidation of low-density lipoproteins (LDL). Oxidation of LDL in vessel wall leads to an inflammatory cascade that activates atherogenic pathway leading to foam cell formation. The accumulation of foam cells leads to fatty streak formation, which is the earliest visible atherosclerotic lesion. In contrast, the cardiac sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA2a) and hepatic apolipoprotein E (apoE) expression can improve cardiovascular function. SERCA2a regulates the cardiac contractile function by lowering cytoplasmic calcium levels during relaxation, and affecting NO(·) action in vascular cells, while apoE is a critical ligand in the plasma clearance of triglyceride- and cholesterol-rich lipoproteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.